Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer

Authors:

Abstract
BACKGROUND: The purpose of this study was to determine the safety and immune responses of pre‐operative personalized peptide vaccine for patients with localized prostate cancer.METHOD: Ten human leukocyte antigen (HLA)‐A24+ patients with localized prostate cancer received weekly personalized peptide vaccine for six times with positive peptides (up to four kinds of peptides) from 16 kinds of vaccine candidates, followed by a retropubic radical prostatectomy (RRP). Eight patients with localized prostate cancer receiving RRP served as the control group. The serum prostate‐specific antigen (PSA) level, and peptide‐specific cytotoxic T lymphocyte (CTL) precursor analysis by interferon‐γ production, and peptide‐reactive immunoglobulin G (IgG) using an enzyme‐linked immunosorbent assay were monitored during the treatment. Distributions of CD45RO+ cells, CD8+ T cells, and CD20+ B cells in tissue microarray samples were studied using an immunohistochemical technique.RESULT: The peptide vaccination was safe and well tolerated with no major adverse effects. Increased CTL response and the anti‐peptide IgG titer were observed in the post‐vaccination samples in 8 of 10 or 8 of 10 patients, respectively. The intensity of CD45RO+ infiltrating cells in the vaccination group was significantly larger than that in the control group. CD8+ T cell infiltration was seen only in the vaccinated group. CONCLUSION: Increased immune responses, at both the circulation and tumor sites in the vaccinated group, support the further development of personalized peptide vaccines for patients with localized prostate cancer. Prostate 67: 933–942, 2007.

This publication has 25 references indexed in Scilit: